HNGE · Hinge Health, Inc. · Stock research

Reference close for every level below: $89.98, the last completed daily close on 2026-08-24 (split/dividend-adjusted daily bars).

HNGE — Hinge Health, Inc.

Current Thesis

The post-print band has resolved upward. After the 2026-08-20 close of $85.62, the tape closed $88.42 on 2026-08-21 and $89.98 on 2026-08-24 — within 1.7% of the $91.57 closing high set 2026-08-10, which is also the 52-week high. RSI(14) reads 68.0 against a three-month price change of +69.8%.

The leg an investor is buying has not changed since the 2026-06-09 mid-quarter raise and its confirmation on 2026-08-04: a digital-MSK operator compounding above 50% while printing GAAP net income and free cash flow, now bolting on a GI franchise for cash. What arrived in the last week is supply rather than operating news. A Form 4 filed 2026-08-21 shows Bessemer Venture Partners X and BVP X Institutional selling 13,527 and 12,699 Class A shares on 2026-08-19 at a weighted average $90.05 — A Form 4 filed 2026-08-24 reports the President selling 33,000 Class A shares on 2026-08-21 under a Rule 10b5-1 plan, with 709,646 shares held after. The only 8-K since the print covers an office lease signed 2026-08-18, not a business development.

The narrative is saturated. The dating is unchanged and now longer in the tooth: at least eight firms revised in the 2026-08-05 session (Needham $97, Barclays $100, Wells Fargo $103, Evercore ISI $105, Citizens $107, RBC $110 among them), the last raise landed 2026-08-11 (Truist $112 from $85), a Mad Money Lightning Round buy call followed 2026-08-12, and no rating action has been published in the nine sessions through 2026-08-24. The distance from $89.98 to the $106.47 panel mean now closes through price alone, because the estimates that would close it were already reset.

Bullish and bearish views on Hinge Health, Inc.

The model's bull view on Hinge Health, Inc. (HNGE), in brief: Q2 2026 revenue $212.817M, +53% YoY, clearing both the self-raised $200–202M floor set 2026-06-09 and the $201.030M consensus; adjusted EPS $0.59 (2026-08-04 release). The bear view: The revision cycle for this print is spent. Both cases follow in full.

Bull Case

• Q2 2026 revenue $212.817M, +53% YoY, clearing both the self-raised $200–202M floor set 2026-06-09 and the $201.030M consensus; adjusted EPS $0.59 (2026-08-04 release).
• Guidance raised at both ends on 2026-08-04: FY2026 to $856–860M from $818–824M, non-GAAP income from operations $236–244M, Q3 to $223–225M against a $211.004M estimate.
• Q2 free cash flow $99.6M, GAAP net income $43.69M, and $476M of cash and equivalents before the Cylinder payment — the $105M cash price is roughly a fifth of that balance (2026-08-04).
• LTM calculated billings $862M, +52% YoY, across nearly 3,000 clients including more than half the Fortune 100 (2026-08-04); bookings running ahead of recognised revenue.

• Repurchase capacity of $300.0M remained open after the 2026-07-29 board increase, against $196.5M already executed of $496.5M authorised since 2025-11-10.
• Panel models still trail the company's own frame: Morgan Stanley's 2026-07-13 raise to $108 was built on CY2026 revenue of $821M, below the $856M floor guided three weeks later.

Bear Case

• The revision cycle for this print is spent. Nine sessions have since passed with no rating action and no operating release.

• Executive selling continued at the top of the range — 33,000 Class A shares on 2026-08-21 under a plan, reported in tranches between $84.802 and $88.2536 (Form 4 filed 2026-08-24).
• The 2026-08-18 lease at 300 Mission Street commits roughly $86M of base rent on about 119,278 rentable square feet through 2037-02-28, with a $17.9M improvement allowance and a one-time early-termination right effective 2035-01-31. A company that crossed into GAAP profitability in Q2 has added an eleven-year fixed obligation.
• RSI(14) 68.0 and +69.8% over three months into a calendar with no scheduled company disclosure: next earnings sit around 2026-11-03.
• Float was 45.39M against 77.38M shares outstanding with 13.73% of float short at the last reported update, so both directions travel further than the fundamentals move.
• Panel dispersion is wide — high $140, low $85 across 16 analysts — and the low target sits beneath the 2026-08-24 close.

Setup & Price Structure

• Post-print band: floor at the 2026-08-20 close of $85.62, ceiling at the 2026-08-10 closing high of $91.57. The 2026-08-24 close of $89.98 sits in the upper third, -1.7% from the high.
• Deeper structure: the June leg broke the $62.18 prior all-time high after the 2026-06-09 raise; that shelf is the second line beneath the current band and roughly 30% lower.
• Crowding observables, stated as observables: RSI(14) 68.0; a retail-facing television buy call dated 2026-08-12; sponsor Form 144 windows opened around 2026-08-19 and running into November; executive 10b5-1 sales arriving on a schedule rather than on news; 13.73% of float short.
• No earnings inside the next 30 days. The only company-generated event that can move the tape before the Q3 print is a Cylinder completion filing.
• INFERRED, not measured: with the estimate reset complete and no operating disclosure due, near-term price is set by whether programme supply is absorbed at these levels rather than by new information.

Catalyst Calendar (next 30 days)

• ~2026-08-31 (est.) — Expected completion of the $105M cash acquisition of Cylinder Health. The 2026-08-04 release states Q3 2026; management narrowed it to end-August/early-September on the call.
• ~2026-09-19 (est.) through ~2026-11-17 — Execution window on the two Bessemer Form 144 notices dated around 2026-08-19; the 2026-08-19 sales are the first tranche and the balance surfaces only in subsequent Form 4s.
• 2026-09-30 — Outer bound of the stated Q3 2026 closing window for Cylinder Health.
• ~2026-11-03 (est.) — Q3 2026 results. Beyond the 30-day window, listed because it is the next scheduled test of the $223–225M Q3 guide and the first checkable Cylinder contribution.

What Would Change Our Mind

The band is the object. Its floor is dated — the 2026-08-20 close of $85.62 — and it was built entirely by the 2026-08-04 print, with sponsor and executive supply now printing inside it. A weekly close below $85 forfeits that floor and puts the tape back on the June breakout shelf near $62.18 with no earnings event until roughly 2026-11-03 to arrest it.

Secondary conditions, each independently observable: no completion 8-K or press release for Cylinder Health by 2026-09-30, which would mean the transaction missed the window management framed on 2026-08-04 and the FY2026 frame loses its acquired contribution; Form 4s working through the balance of the roughly 250,000 notified Bessemer shares while the 2026-08-10 closing high of $91.57 stays unrecovered; or a Q3 guide revision that strips the $7–8M of Cylinder revenue attributed to 2026.

On the other side, a weekly close above $91.57 with no accompanying sponsor Form 4 would say the notified supply is being absorbed rather than capping the tape, and would date the end of the distribution phase described above.

Correlation Notes

• Moves with the digital-health and first-quartile SMID software cohort on multiple, not on MSK fundamentals; the bull targets published between 2026-07-27 and 2026-08-11 are anchored to software comparables rather than healthcare-services ones, so a cohort de-rate compresses them without any Hinge-specific news.
• Enterprise benefits seasonality: client wins for a 1 January launch are contracted during the third-quarter selling season, so the client-count and billings datapoints that matter for 2027 are set before they are disclosed at the Q3 print.
• With 13.73% of float short against a 45.39M float, the name trades with the squeeze-prone end of the recent-IPO complex on days carrying no company headline.
• Direct comparables are split between public (Omada Health) and private (Sword Health), so read-across pricing pressure shows up in Hinge's own billings disclosure rather than in a competitor's tape.